Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-817399 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: Placebo | PLACEBO_COMPARATOR | - |
| Arm 2: BMS-817399 (200 mg) | EXPERIMENTAL | - |
| Arm 3: BMS-817399 (400 mg) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Tablets, Oral, 0 mg, twice daily, 12 weeks |
| BMS-817399 | DRUG | Tablets, Oral, 200 mg, twice daily, 12 weeks |
Inclusion Criteria: * Male or female subjects, 18 years of age or older, with rheumatoid arthritis (RA) for at least 6 months prior to screening * Subjects must have a tender joint count of at least 6 (28 joint count), swollen joint count of at least 6 (28 joint count) at screening. All subjects mu...
Top 20 of 31 competitors
BMS-817399 is an investigational small molecule being studied for the treatment of moderate to severe rheumatoid arthritis. It was evaluated in a Phase 2 proof-of-concept study in adults with the condition. It is not an approved therapy and remains in clinical development.
BMS-817399 targets CCR1, a chemokine receptor, and acts as a CCR1 antagonist. By blocking this receptor, the drug is designed to interfere with CCR1-mediated inflammatory signaling, which is relevant to the immune processes involved in rheumatoid arthritis.
BMS-817399 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 2 proof-of-concept trial of the compound in rheumatoid arthritis.
BMS-817399 is in Phase 2 development. One Phase 2 proof-of-concept trial in moderate to severe rheumatoid arthritis has been completed, and no trials are currently active. The drug is investigational and has not been approved for any indication.
BMS-817399 was studied in NCT01404585, a Phase 2 proof-of-concept trial in moderate to severe rheumatoid arthritis. The trial was randomized, double-blind, and placebo-controlled, enrolled 123 participants, and has been completed. It ran in the United States, Argentina, Mexico, Russia, South Africa, South Korea, and Spain.